Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
PPHMP was delisted on the 5th of January, 2018.
2 hedge funds and large institutions have $3.99M invested in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
30,623% more capital invested
Capital invested by funds: $13K → $3.99M (+$3.98M)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$4.09M |
Top Sellers
PPHMP Hedge Fund Activity: Q4 2016 in Review
2 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) for Q4 2016, worth a combined $3.99M — up 30,623% from $13K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PPHMP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.09M.
- 2 institutional investors held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) as of Q4 2016, up from 1 in Q3 2016.
- Funds reported $3.99M of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible stock for Q4 2016, up 30,623% quarter-over-quarter.
- 1 fund opened new Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible buyer in Q4 2016 was Perceptive Advisors, an estimated $4.09M added.
Based on aggregated 13F filings for Q4 2016.